Debiopharm And Alkyon Therapeutics Announce Research Collaboration To Advance The Next Generation Of Radioligand Therapies
“This collaboration reflects our shared commitment to expanding the potential of radioligand therapies,” said Benjamin Titz, Co-Founder and CEO of Alkyon Therapeutics. “By applying AbYlink™ to our specialized antibody scaffolds and targeting strategies tailored to the unique architecture of solid tumors, we aim to unlock new therapeutic possibilities and advance care for patients with difficult-to-treat solid tumors.”
Share:
More News
“Orphan Drug Designation for SOT106 underscores both the urgent need for new treatment options in osteosarcoma and the strength of our ADC platform,” said Radek Spisek, M.D., Ph.D., chief executive officer of SOTIO. “Osteosarcoma is a devastating disease that has seen little therapeutic innovation over the past four decades. Treatment
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two